ANVS CEO Maccecchini purchases 97,561 shares at $2.05 amid pre-clinical stage biotech; stock down 71.8% from 52-week high
Maccecchini Maria-Luisa, the President & CEO of Annovis Bio, purchased 97,561 shares at $2.05 for $200,000.05 on 2025-10-28, increasing her holdings from 1,114,459 to 1,212,020 shares (an 8.8% increase in her stake). The purchase occurs while the company is unprofitable with net income of -$7,262,658.00 for its most recent full fiscal year and zero revenue in the latest quarter, reflecting a clinical-stage or pre-commercial biotech with no product revenues yet. The stock trades at $2.43 currently, down 71.8% from its 52-week high of $8.61, but has risen 46.4% over the past 30 days from the transaction date perspective. An insider equity purchase by the CEO represents a material increase in personal financial exposure to the company's risk profile during a period of significant share price volatility and fundamental losses.